Development

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

TruGolf Announces Global Franchising with Franchise Well to Accelerate Growth

Retrieved on: 
Wednesday, March 27, 2024
Well, Principal, Ageing, Golf, Growth, Development, Video game

This relationship marks a pivotal moment for TruGolf as it harnesses the power of franchising to amplify its global presence and cater to the burgeoning demand for immersive off-course golf experiences.

Key Points: 
  • This relationship marks a pivotal moment for TruGolf as it harnesses the power of franchising to amplify its global presence and cater to the burgeoning demand for immersive off-course golf experiences.
  • This collaboration comes at a time when the franchising market is experiencing a significant shift towards experience-based and recreational concepts.
  • Franchising serves as a capital-efficient model to drive our growth and fuel global expansion.
  • This relationship with Franchise Well accelerates our growth and allows us to deploy our innovative technology to even more enthusiasts around the world.”
    The collaboration with Franchise Well will propel TruGolf’s growth strategy forward through the regional developer franchise model, targeting seasoned franchise owners to spearhead expansion.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Blood pressure, Body composition, LDL, Adipose tissue, Obesity, Development, Cirrhosis, Three Months, Exercise, Arrhythmia, Hepatitis B virus, Diabetes, Lipid, Patient, Heart rate, Fast Track, Weight loss, Sarcopenia, MASH, Woman, Diet, Investment, Fibrosis, Safety, Optimism, FDA, Triglyceride, IMPACT, Dietary supplement

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

Actelis Networks Reports Fiscal Full Year 2023 Results

Retrieved on: 
Tuesday, March 26, 2024
UL, Research, ASNS, Department of Defence, Certification, Temperature, Development, Interoperability, Partnership, Operating cost, City, IPO, Bret Harrison, Senior, Marketing, NIST, Investment, FIPS, Public sector, Airport, MDU, Cryptocurrency

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, hybrid-fiber rapid deployment networking solutions for wide area IoT applications, today reported financial results for the fiscal full year 2023 ended December 31, 2023.

Key Points: 
  • FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, hybrid-fiber rapid deployment networking solutions for wide area IoT applications, today reported financial results for the fiscal full year 2023 ended December 31, 2023.
  • Direct margin increase: Gross Margin was 34% for the full year 2023, compared to 47% in the prior year.
  • Substantial improvement in operating expenses: Operating expenses declined by 9% to $9.3 million for the full year 2023.
  • Fiscal Full Year 2023 Financial Highlights:
    Revenues for the year ended December 31, 2023 amounted to $5.6 million, compared to $8.8 million for the year ended December 31, 2022.

Linklogis Announces 2023 Annual Results: Maintaining the Largest Market Share in China for 4 Consecutive Years

Retrieved on: 
Tuesday, March 26, 2024
Cloud, Transfer, Vietnamese, PDD, OPPO, Contribution, Standard Chartered, GPT, Intellectual property, Bank, Sustainalytics, Social responsibility, Multi, Risk assessment, Supply chain, SME, Share repurchase, Digital, Intelligence, ESG, TBI, Acquisition, AI, Ecology, ChatGPT, Development, Growth, Blockchain, KYC, Cross, CMMI, Infor, LDP, Cryptocurrency

Beijing, China, March 26, 2024 (GLOBE NEWSWIRE) -- On March 26, 2024, Linklogis Inc. (09959.HK, “Linklogis”), a leading supply chain finance technology solution provider in China, released its 2023 annual results.

Key Points: 
  • Beijing, China, March 26, 2024 (GLOBE NEWSWIRE) -- On March 26, 2024, Linklogis Inc. (09959.HK, “Linklogis”), a leading supply chain finance technology solution provider in China, released its 2023 annual results.
  • The board of directors of Linklogis proposes to pay a special dividend of HK$0.1 per share, totaling approximately HK$230 million.
  • Furthermore, the board expresses confidence in the company’s prospects and sustained growth in the future, and announces a share repurchase plan of up to US$100 million.
  • According to China Insights Consultancy, Linklogis held 20.9% market share, ranking No.1 in the third-party supply chain finance technology solutions providers in China for the fourth consecutive year.

Preparations Begin in Downtown Detroit for 2024 NFL Draft Presented by Bud Light

Retrieved on: 
Tuesday, March 26, 2024
Friends, National Football League Draft, Cadillac, City, Michigan Economic Development Corporation, Transport, DTE Energy, NFL Network, Phase 1, Fan service, Restaurant, NFL, General Motors, Penske Corporation, Columbia Street, ESPN, Huntington Bancshares, Flagstar Bank, Detroit Lions, The Development, ESPN Deportes, Detroit Partnership, State, ABC, Conscription, Development, W. K. Kellogg Foundation, Detroit Pistons, Theatre, Philip A. Hart Plaza, Knight Foundation, DDP, Football, Corktown, Corner Ballpark, DDOT, Rocket Mortgage, M-1 (Michigan highway), Smartphone, Fifth Third Bank, PNC Financial Services, RTA, Beacon Park, SMART, Nightclub

The announcement, marking 30 days before night one of the Draft on April 25, took place at the Development at Cadillac Square—formerly known as the Monroe Midway—the site of the NFL Draft Theater.

Key Points: 
  • The announcement, marking 30 days before night one of the Draft on April 25, took place at the Development at Cadillac Square—formerly known as the Monroe Midway—the site of the NFL Draft Theater.
  • During the media event, the City announced the first downtown street closures for the Draft, which is expected to attract hundreds of thousands of visitors and customers for downtown businesses.
  • “The Downtown Detroit Partnership’s ‘Draft Day in the D’ is free to fans, friends, and families who will be enjoying Detroit during Draft Weekend,” said Downtown Detroit Partnership CEO Eric B. Larson.
  • For more information on the NFL Draft presented by Bud Light, fans should visit nfl.com/draft/event-info and download the NFL OnePass app or on the web at NFL.com/DraftAccess .

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Retrieved on: 
Tuesday, March 26, 2024
Development, Growth, Skin cancer, Immunotherapy, Genentech, Philip, Patient, Lung, RP1, Skin, Cancer, Melanoma, Retirement, Marketing, BLA

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.

Key Points: 
  • Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024.
  • Mr. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors.
  • Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer.
  • Prior to joining Replimune, Dr. Patel served as franchise head for lung, skin and rare cancers at Genentech.

The Kraft Heinz Company Foundation Commits $15 Million Over Three Years to Rise Against Hunger to Provide 463 Million Meals to People in Need

Retrieved on: 
Tuesday, April 9, 2024
Other Philanthropy, Women, Men, Sustainability, Family, Consumer, Environmental, Social and Governance (ESG), Environment, Teens, Children, Fitness & Nutrition, Professional Services, Philanthropy, Health, Fund Raising, Foundation, Vitamins, Supplements, Agriculture, Other Consumer, Natural Resources, Kraft Heinz, COVID, Partnership, Rise Against Hunger, Food, Hunger, Mineral, Flood, Development, Multimedia, Meal, Emerging market, Fast-moving consumer goods

Today, The Kraft Heinz Company Foundation announces an extended three-year partnership and $15 million commitment to Rise Against Hunger , an international nonprofit organization.

Key Points: 
  • Today, The Kraft Heinz Company Foundation announces an extended three-year partnership and $15 million commitment to Rise Against Hunger , an international nonprofit organization.
  • The commitment builds on a decade-long partnership between Kraft Heinz and Rise Against Hunger to alleviate global hunger and improve access to nutrition.
  • View the full release here: https://www.businesswire.com/news/home/20240409900011/en/
    Kraft Heinz employees pack meals during the annual Packathon (Photo: Business Wire)
    “At Kraft Heinz, we aim to provide 1.5 billion meals to people in need by 2025,” said Andrea Budelli, President of The Kraft Heinz Company Foundation and Chief R&D Officer of Developed & Emerging Markets at Kraft Heinz.
  • This impact includes:
    Fortified more than 127 million Rise Against Hunger meals with 21 million micronutrient sachets for school feeding and dietary supplementation programs.

Avangrid Recognized for Job Quality Performance by JUST Capital

Retrieved on: 
Tuesday, April 9, 2024
Other Energy, Utilities, Environment, Oil, Gas, Sustainability, Alternative Energy, Energy, Development, Parental leave, Knowledge, Scorecard, Fertility, Capital, JUST, Life, Investment, Compensation, Curriculum, AGR

Avangrid earned top marks in the categories of Employee Wellness and Training & Development and earned an overall score well above the energy industry average.

Key Points: 
  • Avangrid earned top marks in the categories of Employee Wellness and Training & Development and earned an overall score well above the energy industry average.
  • We recognize that prioritizing job quality also creates a positive ripple effect that extends to our customers, shareholders, and society at large.
  • It creates a standard by assessing job quality performance on 31 data points across six key topic areas: Benefits, Employee Wellness, Hiring & Stability, Training & Development, Wages & Compensation, and Workforce Composition.
  • In 2023, Avangrid employees logged a total of 20,051 hours of leadership training and 13,260 online leadership course training hours.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Tuesday, April 9, 2024
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Development, Risk, Diabetes, Ageing, Chronic obstructive pulmonary disease, Head, RSV, Senior, Asthma, Safety, Vaccine, Person

Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.

Key Points: 
  • Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.
  • However, no RSV vaccines have been approved for use in adults 18 to 59 years of age.
  • The MONeT study was initiated to address this significant unmet need by investigating the immunogenicity and safety of ABRYSVO in adults aged 18 to 59 at increased risk for RSV disease, such as those with asthma, diabetes, and chronic obstructive pulmonary disease.
  • “These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer.